FREMONT, Calif., Oct. 22, 2015 (GLOBE NEWSWIRE) -- WaferGen Bio-systems (NASDAQ:WGBS) announced today that the Company has signed a supply agreement with Reprogenetics, the largest U.S. genetics laboratory specializing in Preimplantation Genetic Screening (PGS) and Preimplantation Genetic Diagnosis (PGD), for use of WaferGen's Apollo 324TM Next Generation Sequencing (NGS) sample preparation system. The Apollo 324™ will enable automation of NGS library preparation for PGS testing used in in-vitro fertilization (IVF).
The Apollo 324™ is a compact and versatile platform that enables rapid and full walk-away library prep automation for NGS applications. It combines precise liquid handling and proven chemistries to provide a streamlined sample-to-answer solution for robust library preparation on all major NGS platforms.
"We look forward to supporting the leader in PGS and PGD testing, as Reprogenetics continues to deliver high-quality personalized care in the IVF field," said Rollie Carlson, CEO of WaferGen Bio-systems. "The Apollo 324™ NGS sample preparation system will enable improved workflow and will create additional resources for Reprogenetics' transition of their PGS services to NGS."
About WaferGen
WaferGen Bio-systems, Inc. is a biotechnology company that offers innovative genomic technology solutions for single-cell analysis and clinical research. The ICELL8™ Single-Cell System is a revolutionary platform which can isolate thousands of single cells and processes specific cells for analysis, including Next Generation Sequencing. The system has demonstrated unbiased isolation of up to 1,800 single cells ranging from 5-100 µm in size on a single chip, including single cells from solid tumors, brain cells, pulmonary airway cells, and multiple cell lines. The SmartChip platform can be used for profiling and validating molecular biomarkers, and can perform massively-parallel single-plex PCR for one-step target enrichment and library preparation for clinical NGS. These technologies offer a powerful set of tools for biological analysis at the molecular and single-cell level in the life sciences, pharmaceutical and clinical laboratory industries.
Forward Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities and Exchange Act of 1934, as amended that are intended to be covered by the "safe harbor" created by those sections. Forward-looking statements, which are based on certain assumptions and describe our future plans, strategies and expectations, can generally be identified by the use of forward-looking terms such as "believe," "expect," "may," "will," "should," "could," "seek," "intend," "plan," "estimate," "anticipate" or other comparable terms. Forward-looking statements in this press release may address the following subjects among others: statements regarding the sufficiency of our capital resources, expected operating losses, expected revenues, expected expenses, expected cash usage, our expectations regarding our development of future products including single cell analysis technologies and our expectations concerning our competitive position and business strategy. Forward-looking statements involve inherent risks and uncertainties which could cause actual results to differ materially from those in the forward-looking statements, as a result of various factors including those risks and uncertainties described in the Risk Factors and in Management's Discussion and Analysis of Financial Condition and Results of Operations sections of our most recently filed Annual Report on Form 10-K and any subsequently filed Quarterly Reports on Form 10-Q. We urge you to consider those risks and uncertainties in evaluating our forward-looking statements. We caution readers not to place undue reliance upon any such forward-looking statements, which speak only as of the date made. Except as otherwise required by the federal securities laws, we disclaim any obligation or undertaking to publicly release any updates or revisions to any forward-looking statement contained herein (or elsewhere) to reflect any change in our expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based.